A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
Pharmacogenomics of glibenclamide in patients with type 2 diabetes mellitus: A systematic review
2022
Majallah-i ̒Ilmī-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Simnān
One of the most widely used anti-diabetic drugs is sulfonylureas, which is often used as one of the first-line drugs in the treatment of type 2 diabetes. Due to the effect of the patient's genetic structure on the drug response (personalized medicine), the identification of genetic variations not only reduces the rate of adverse drug reactions but can also predict the effectiveness of drugs. This study aimed to systematically review the pharmacogenomics of glibenclamide in type 2 diabetes.
doaj:c62f01b9fcfb462bacd8faa3aab2f0cf
fatcat:vqfym5ui7nh5lhg4hyhr7bm3hu